Skip to main content

Table 1 Characteristics of patients receiving a first-line treatment for advanced NSCLC in the pre– and post–I-O periods

From: Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

 

Pre–I-O

(1 January 2010–31 March 2016)

Post–I-O

(1 April 2016–30 June 2019)

All (N = 1501)a

NSQ (n = 1026)

SQ (n = 225)

All (N = 743)b

NSQ (n = 553)

SQ (n = 129)

Age,c years

Median

Q1–Q3

Range

65

58–72

26–91

64

56–72

26–91

68

61–72

39–85

68

60–74

27–96

66

59–74

27–96

69

63–73

43–86

Female, n (%)

763 (50.8)

555 (54.1)

85 (37.8)

388 (52.2)

314 (56.8)

42 (32.6)

Initial TNM stage, n (%)

I–IIIAd

159 (10.6)

89 (8.7)

46 (20.4)

129 (17.4)

85 (15.4)

38 (29.5)

IIIB

186 (12.4)

102 (9.9)

53 (23.6)

83 (11.2)

46 (8.3)

31 (24.0)

IV

1156 (77.0)

835 (81.4)

126 (56.0)

531 (71.5)

422 (76.3)

60 (46.5)

Location of metastases, n (%)

Visceral, excl. adrenal/liver

390 (26.0)

297 (28.9)

35 (15.6)

192 (25.8)

157 (28.4)

22 (17.1)

Bone

259 (17.3)

194 (18.9)

26 (11.6)

118 (15.9)

100 (18.1)

12 (9.3)

Liver

144 (9.6)

102 (9.9)

15 (6.7)

43 (5.8)

35 (6.3)

5 (3.9)

Brain

132 (8.8)

109 (10.6)

 < 5

88 (11.8)

75 (13.6)

7 (5.4)

Lymph

114 (7.6)

76 (7.4)

17 (7.6)

58 (7.8)

43 (7.8)

9 (7.0)

Adrenal

80 (5.3)

61 (5.9)

8 (3.6)

40 (5.4)

34 (6.1)

 < 5

CCI, n (%)

0

477 (31.8)

331 (32.3)

69 (30.7)

229 (30.8)

178 (32.2)

34 (26.4)

1

345 (23.0)

222 (21.6)

66 (29.3)

164 (22.1)

114 (20.6)

39 (30.2)

2

159 (10.6)

102 (9.9)

32 (14.2)

76 (10.2)

54 (9.8)

17 (13.2)

3

202 (13.5)

147 (14.3)

23 (10.2)

93 (12.5)

69 (12.5)

17 (13.2)

4 + 

318 (21.2)

224 (21.8)

35 (15.6)

181 (24.4)

138 (25.0)

22 (17.1)

  1. Unless otherwise indicated, all characteristics were recorded at time of diagnosis. Data were masked when patient numbers for an individual category were greater than zero but less than 5
  2. Abbreviations: CCI Charlson Comorbidity Index; I-O immuno-oncology; NOS not otherwise specified; NSCLC non-small cell lung cancer; NSQ non-squamous; Q quartile; SQ squamous; TNM tumor, nodes, metastasis
  3. aPatients had NSQ (n = 1026), SQ (n = 225), NOS (n = 226) or Other (n = 24) histology
  4. bPatients had NSQ (n = 553), SQ (n = 129), NOS (n = 52) or Other (n = 9) histology
  5. cAge recorded at start of first-line treatment for advanced NSCLC
  6. dPatients with TNM stage I–IIIA NSCLC at diagnosis represent “progressed patients” who subsequently received systemic anticancer therapy during the study period (see Additional file 1)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us